GSK oncology outlook seen as underappreciated, JPM says

J.P. Morgan says GSK CEO Luke Miels told analysts the company’s oncology business is underappreciated and reiterated confidence in meeting its 2031 sales target of more than 40 billion pounds. The bank said upcoming updates at a medical congress could improve investor confidence in the pipeline.